Illumina, Inc. $ILMN Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 4.0% in the 3rd quarter, Holdings Channel.com reports. The firm owned 185,832 shares of the life sciences company’s stock after selling 7,647 shares during the quarter. Retirement Systems of Alabama’s holdings in Illumina were worth $17,648,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ILMN. WCM Investment Management LLC increased its position in shares of Illumina by 5.9% in the second quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock valued at $419,585,000 after buying an additional 247,460 shares in the last quarter. Loomis Sayles & Co. L P grew its stake in Illumina by 1.9% in the 2nd quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock valued at $403,158,000 after acquiring an additional 78,317 shares during the period. AQR Capital Management LLC increased its holdings in Illumina by 55.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after acquiring an additional 1,174,295 shares in the last quarter. Geode Capital Management LLC raised its position in Illumina by 0.7% during the second quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock worth $272,921,000 after acquiring an additional 21,342 shares during the period. Finally, Bank of America Corp DE lifted its holdings in Illumina by 1.9% during the second quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock valued at $184,222,000 after purchasing an additional 35,167 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity

In other news, Director Scott Gottlieb purchased 500 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was acquired at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the acquisition, the director directly owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the transaction, the insider owned 17,887 shares in the company, valued at $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.17% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on ILMN shares. TD Cowen reissued a “hold” rating on shares of Illumina in a research note on Wednesday, January 7th. JPMorgan Chase & Co. boosted their price objective on Illumina from $105.00 to $130.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. Weiss Ratings restated a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Evercore ISI reiterated an “outperform” rating and set a $155.00 price target on shares of Illumina in a research report on Monday, January 5th. Finally, Zacks Research lowered Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. Six equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $127.18.

Illumina Stock Performance

Shares of Illumina stock opened at $153.00 on Tuesday. The business’s 50 day moving average price is $135.86 and its 200 day moving average price is $113.72. The company has a market cap of $23.38 billion, a price-to-earnings ratio of 34.30, a PEG ratio of 2.49 and a beta of 1.41. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. Illumina, Inc. has a one year low of $68.70 and a one year high of $155.53.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the prior year, the business earned $1.14 EPS. The firm’s quarterly revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, research analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.